GaiaLab — Validated Predictions

📅

Prospective Tracking Started May 19, 2026

Every new analysis from today is timestamped in real time. When a trial registers on ClinicalTrials.gov after GaiaLab scored that drug-disease pair, it counts as a genuine forward prediction. Return in 30, 60, and 90 days to see prospective predictions accumulate. No cherry-picking — every scored pair is in the ledger.

Prospective tracking active for: 0 days

· All — name-matched ledger matches are retrospective (trial pre-dates our analysis)

Separately, semantic matching surfaced 15 prospective matches ↗ where the prediction pre-dates the trial — but in honest terms, 13 are on-label concordance (the drug is already standard-of-care, so the lead-time isn't foresight) and only 2 are genuine off-label repurposing hypotheses.

Recently Registered Trials Matching Our Benchmark

Trials registered 2023–2026 for drugs GaiaLab scores highly

These trials were registered recently. GaiaLab surfaces these drugs through evidence scoring — independent of trial registration data. All matches in this name-matched ledger are retrospective: the drug-disease pair appeared in our scoring before we checked CT.gov, but the trial itself pre-dates May 2026. (Semantic matching surfaces prospective matches separately — see /new-trials.)

Drug	Disease	NCT ID	Trial Registered	Why GaiaLab Scores It
Lecanemab	Alzheimer's disease	NCT07212062 ↗	Oct 2025	Anti-amyloid mAb; APOE, APP, PSEN panel targets; published Phase 3 efficacy
Lorlatinib	Non-small cell lung cancer	NCT06893354 ↗	Mar 2025	3rd-gen ALK/ROS1 inhibitor; high CIViC/ChEMBL evidence for EGFR/ALK NSCLC
Carboplatin	Triple-negative breast cancer	NCT06845319 ↗	Feb 2025	DNA damage repair; BRCA1/TP53 targets; strong mechanistic alignment with TNBC
Gemcitabine	Pan-cancer	NCT06991491 ↗	May 2025	Nucleoside analog; broad oncology evidence across KRAS/TP53 panels
Adagrasib	Colorectal cancer	NCT05198934 ↗	Sep 2023	KRAS G12C inhibitor; BRAF/KRAS/NRAS panel; FDA-approved for NSCLC/CRC

What the — Matches Represent

Domain intelligence, not database lookup

The — matches include precision oncology agents, emerging Alzheimer's therapies, targeted AML drugs, and novel KRAS inhibitors — not random concordance. GaiaLab scores these through mechanistic pathway alignment, target overlap, and clinical evidence depth.

Targeted Oncology

Adagrasib · Dabrafenib · Encorafenib
Lorlatinib · Osimertinib · Alectinib
Brigatinib · Selumetinib · Tovorafenib

KRAS · BRAF · ALK · EGFR inhibitors

Alzheimer's Emerging Therapies

Lecanemab · Donanemab
Aducanumab · Gantenerumab
Solanezumab

Anti-amyloid antibodies · APP/APOE/PSEN panels

Precision AML

Gilteritinib · Quizartinib
Midostaurin · Ponatinib
Pacritinib

FLT3 · BCR-ABL · JAK2 targeted agents

Immunotherapy

Atezolizumab · Cetuximab
Amivantamab · Panitumumab
Bevacizumab

PD-L1 · EGFR · VEGF · bispecific agents

Retrospective Concordance — Transparent Methodology

GaiaLab queries the ClinicalTrials.gov API v2. A drug-disease pair is counted as a concordance match when a registered trial exists for that exact pair. All — matches in this name-matched ledger are retrospective — the trial was registered before our analysis. (A separate semantic-matching layer has surfaced 15 prospective matches, of which only 2 are genuine off-label repurposing hypotheses — the rest are on-label concordance.) Completed trial status does not imply positive outcome.

Prediction Calibration by Confidence Level

—

Trial Match Rate — drug-disease pair appears in ClinicalTrials.gov

Research Direction Rate — matches research direction in literature

Most Confirmed Drugs

By ClinicalTrials.gov match count

Disease Coverage

—

Full Predictions Ledger

Loading…

Drug	Disease	Key Targets	Trial (NCT)	Trial Status	Verdict	Predicted

GaiaLab's retrospective benchmark.— drug-disease pairs GaiaLab scores highlyhave matching ClinicalTrials.gov trials.